IOL Chemicals and Pharmaceuticals Limited
NSE: IOLCP · Pharmaceuticals
Snapshot
Unlock IOL Chemicals and Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
IOL Chemicals and Pharmaceuticals Limited is a manufacturer of active pharmaceutical ingredients (APIs) and specialty industrial chemicals. The company serves a diverse range of sectors including pharmaceuticals, food processing, textiles, and packaging.
Business Model
The company generates revenue through the large-scale production and sale of APIs, notably ibuprofen, and specialty chemicals such as ethyl acetate and iso butyl benzene. It operates as both a domestic supplier and an international exporter.
Growth Outlook
Growth is driven by the expansion of its API portfolio and the sustained demand for its specialty chemical intermediates across multiple industrial applications.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from global health authorities, where non-compliance could lead to export restrictions.
- Raw Material Price Volatility. Fluctuations in the cost of chemical feedstocks and petrochemical derivatives can significantly impact profit margins.
- Currency Risk. As an exporter, the company is exposed to foreign exchange rate volatility which may affect its international competitiveness and earnings.
- Commodity Price Sensitivity. The specialty chemicals segment is susceptible to cyclical demand and price pressures within the global industrial chemical market.
Start your research today
Unlock AI insights, financials, peers and live data on IOL Chemicals and Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,524 Cr
TTM · consolidated
NET PROFIT
₹168 Cr
TTM · consolidated
EPS
₹5.73
TTM · consolidated
RETURN ON EQUITY
9.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
13.1%
TTM · consolidated
P/E
34.9x
Q1 FY27 · consolidated
EV/EBITDA
17.9x
Q1 FY27 · consolidated
EBITDA MARGIN
13.2%
TTM · consolidated
NET PROFIT MARGIN
8.5%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.1x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
IOL Chemicals and Pharmaceuticals LimitedIOLCP | ₹5,869 Cr | 34.90 | 17.85 | 18.6% | 13.2% | 9.6% | 13.1% | +103.6% |
Senores Pharmaceuticals Ltd.SENORES | ₹6,578 Cr | 50.30 | 29.26 | — | 34.7% | 15.2% | 18.4% | +102.9% |
Sun Pharma Advanced Research Company LimitedSPARC | ₹6,473 Cr | 4.09 | 4.28 | 2855.8% | 86.0% | 282.4% | 235.1% | +38.2% |
Jeena Sikho Lifecare LimitedJSLL | ₹6,418 Cr | 27.15 | 16.65 | — | 45.2% | 50.6% | 58.2% | -33.7% |
Morepen Laboratories LimitedMOREPENLAB | ₹6,232 Cr | 44.43 | 31.03 | 9.5% | 10.6% | 11.7% | 14.4% | +129.7% |
FDC LimitedFDC | ₹5,581 Cr | 19.07 | 11.66 | 3.4% | 21.7% | 12.3% | 16.1% | -25.5% |
As of Q1 FY27
Financials
IOL Chemicals and Pharmaceuticals Limited
NSE: IOLCP · Pharmaceuticals
Snapshot
Unlock IOL Chemicals and Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
IOL Chemicals and Pharmaceuticals Limited is a manufacturer of active pharmaceutical ingredients (APIs) and specialty industrial chemicals. The company serves a diverse range of sectors including pharmaceuticals, food processing, textiles, and packaging.
Business Model
The company generates revenue through the large-scale production and sale of APIs, notably ibuprofen, and specialty chemicals such as ethyl acetate and iso butyl benzene. It operates as both a domestic supplier and an international exporter.
Growth Outlook
Growth is driven by the expansion of its API portfolio and the sustained demand for its specialty chemical intermediates across multiple industrial applications.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from global health authorities, where non-compliance could lead to export restrictions.
- Raw Material Price Volatility. Fluctuations in the cost of chemical feedstocks and petrochemical derivatives can significantly impact profit margins.
- Currency Risk. As an exporter, the company is exposed to foreign exchange rate volatility which may affect its international competitiveness and earnings.
- Commodity Price Sensitivity. The specialty chemicals segment is susceptible to cyclical demand and price pressures within the global industrial chemical market.
Start your research today
Unlock AI insights, financials, peers and live data on IOL Chemicals and Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,524 Cr
TTM · consolidated
NET PROFIT
₹168 Cr
TTM · consolidated
EPS
₹5.73
TTM · consolidated
RETURN ON EQUITY
9.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
13.1%
TTM · consolidated
P/E
34.9x
Q1 FY27 · consolidated
EV/EBITDA
17.9x
Q1 FY27 · consolidated
EBITDA MARGIN
13.2%
TTM · consolidated
NET PROFIT MARGIN
8.5%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.1x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27